Statins and risk of polyneuropathy
A case-control study
Abstract
Background: Several case reports and a single epidemiologic study indicate that use of statins occasionally may have a deleterious effect on the peripheral nervous system. The authors therefore performed a population-based study to estimate the relative risk of idiopathic polyneuropathy in users of statins.
Method: The authors used a population-based patient registry to identify first-time-ever cases of idiopathic polyneuropathy registered in the 5-year period 1994 to 1998. For each case, validated according to predefined criteria, 25 control subjects were randomly selected among subjects from the background population matched for age, sex, and calendar time. The authors used a prescription register to assess exposure to drugs and estimated the odds ratio of use of statins (ever and current use) in cases of idiopathic polyneuropathy compared with control subjects.
Results: The authors verified a diagnosis of idiopathic polyneuropathy in 166 cases. The cases were classified as definite (35), probable (54), or possible (77). The odds ratio linking idiopathic polyneuropathy with statin use was 3.7 (95% CI 1.8 to 7.6) for all cases and 14.2 (5.3 to 38.0) for definite cases. The corresponding odds ratios in current users were 4.6 (2.1 to 10.0) for all cases and 16.1 (5.7 to 45.4) for definite cases. For patients treated with statins for 2 or more years the odds ratio of definite idiopathic polyneuropathy was 26.4 (7.8 to 45.4).
Conclusions: Long-term exposure to statins may substantially increase the risk of polyneuropathy.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Danish National Medicines Division. Lægemiddelstatistik, Danmark, 1994–1998 [in Danish]. Copenhagen: Department of Statistics, Medicines Division, 1999.
2.
Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid-lowering drugs in general practice. BMJ . 1998; 317: 1134–1135.
3.
Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet . 1994; 344: 1383–1389.
4.
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Group. N Engl J Med . 1995; 333: 1301–1307.
5.
Jacobs MB. HMG-CoA reductase inhibitor therapy and peripheral neuropathy. Ann Intern Med . 1994; 120: 970.
6.
Ahmad S. Lovastatin and peripheral neuropathy. Am Heart J . 1995; 130: 1321.
7.
Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern J-P. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry . 1995; 58: 625–628.
8.
Ziajka PE, Wehmeier T. Peripheral neuropathy and lipid-lowering therapy. South Med J . 1998; 91: 667–668.
9.
Jeppesen U, Gaist D, Smith T, Sindrup SH. Statins and peripheral neuropathy. Eur J Clin Pharmacol . 1999; 54: 835–838.
10.
Gaist D, García Rodríguez LA, Huerta C, Hallas J, Sindrup SH. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol . 2001; 56: 931–933.
11.
Gaist D, Sørensen HT, Hallas J. Danish prescription registries. Dan Med Bull . 1997; 44: 445–448.
12.
WHO Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical (ATC) classification index including defined daily doses (DDDs) for plain substances. Oslo: WHO, 1995.
13.
Le Quesne PM. Neuropathy due to drugs. In: Dyck PJ, Thomas PK, Griffin JW, et al, eds. Peripheral neuropathy. 3rd ed. Philadelphia: Saunders, 1993: 1571–1581.
14.
Dukes NMG, Aronson JK, eds. Meyler’s side effects of drugs. 14th ed. Amsterdam: Elsevier, 2000.
15.
Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case-control studies: “the number of patients needed to be treated for one additional patient to be harmed”. BMJ . 2000; 320: 503–506.
16.
StataCorp. Stata statistical software: release 6.0. College Station, TX: Stata Corp, 1999.
17.
Lovastatin study groups I through IV. Lovastatin 5-year safety and efficacy study. Arch Intern Med 1993;153:1079–1087.
18.
McManis PG, Windeback AJ, Kiziltan M. Neuropathy associated with hyperlipidemia. Neurology . 1994; 44: 2185–2186.
19.
MacDonald BK, Cockerell OC, Sander WAS, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain . 2000; 123: 665–676.
Information & Authors
Information
Published In
Copyright
© 2002.
Publication History
Received: December 18, 2001
Accepted: February 16, 2002
Published online: May 14, 2002
Published in print: May 14, 2002
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Observational case-control study of small-fiber neuropathies, with regards on smoking and vitamin D deficiency and other possible causes, Frontiers in Medicine, 9, (2023).https://doi.org/10.3389/fmed.2022.1051967
- Evaluation of anti-atherosclerotic potential of Tinospora cordifolia in high-fat diet-induced atherosclerosis with associated changes in histological and biochemical parameters on Wistar rats, Future Journal of Pharmaceutical Sciences, 9, 1, (2023).https://doi.org/10.1186/s43094-023-00488-y
- Study on risk factors of diabetic peripheral neuropathy and establishment of a prediction model by machine learning, BMC Medical Informatics and Decision Making, 23, 1, (2023).https://doi.org/10.1186/s12911-023-02232-1
- Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association, Arteriosclerosis, Thrombosis, and Vascular Biology, 43, 10, (2023).https://doi.org/10.1161/ATV.0000000000000164
- Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics, Cardiovascular Endocrinology and Metabolism, (97-135), (2023).https://doi.org/10.1016/B978-0-323-99991-5.00012-7
- Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitability—Evidence from ApoE-/- Mice, International Journal of Molecular Sciences, 23, 10, (5415), (2022).https://doi.org/10.3390/ijms23105415
- Ginkgetin promotes proliferation and migration of Schwann cells via PIGF/p38 MAPK signaling pathway, Tissue and Cell, 79, (101967), (2022).https://doi.org/10.1016/j.tice.2022.101967
- Statin therapy for the primary prevention of cardiovascular disease: Cons, Atherosclerosis, 356, (46-49), (2022).https://doi.org/10.1016/j.atherosclerosis.2022.07.003
- Medicinal chemistry and pharmacology of statins, Cholesterol, (903-926), (2022).https://doi.org/10.1016/B978-0-323-85857-1.00012-2
- The conundrum and enigma of painful and painless neuropathy, Diabetic Neuropathy, (123-133), (2022).https://doi.org/10.1016/B978-0-12-820669-0.00012-8
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.